BRPI0908098A2 - Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 - Google Patents

Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2

Info

Publication number
BRPI0908098A2
BRPI0908098A2 BRPI0908098-8A BRPI0908098A BRPI0908098A2 BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2 BR PI0908098 A BRPI0908098 A BR PI0908098A BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2
Authority
BR
Brazil
Prior art keywords
treating
compound
beloxepine
antagonizing
reuptake
Prior art date
Application number
BRPI0908098-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Bertrand Le Bourdonnec
Roland Dolle
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of BRPI0908098A2 publication Critical patent/BRPI0908098A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0908098-8A 2008-02-19 2009-02-19 Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 BRPI0908098A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2991308P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US2991508P 2008-02-19 2008-02-19
US5092108P 2008-05-06 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0908098A2 true BRPI0908098A2 (pt) 2015-08-18

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908098-8A BRPI0908098A2 (pt) 2008-02-19 2009-02-19 Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2

Country Status (11)

Country Link
EP (1) EP2285818A4 (de)
JP (1) JP2011512414A (de)
KR (1) KR20100137473A (de)
CN (1) CN102007139A (de)
AU (1) AU2009215541A1 (de)
BR (1) BRPI0908098A2 (de)
CA (1) CA2715192A1 (de)
IL (1) IL207668A0 (de)
MX (1) MX2010009110A (de)
NZ (2) NZ594937A (de)
WO (1) WO2009105507A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
OA12969A (en) * 2002-12-11 2006-10-13 Pharmacia & Upjohn Co Llc Combination for the treatment of ADHD.
BRPI0415683A (pt) * 2003-11-03 2006-12-19 Warner Lambert Co inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
EP1828156A2 (de) * 2004-12-13 2007-09-05 Arena Pharmaceuticals, Inc. N-biaryl- und n-arylheteroarylpiperazinderivate als modulatoren des 5ht2c-rezeptors, die sich für die behandlung von damit in zusammenhang stehenden erkrankungen eignen
CN101107254B (zh) * 2005-01-27 2010-12-08 詹森药业有限公司 在中枢神经系统病症的治疗中作为5ht2抑制剂的杂环四环四氢呋喃衍生物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1934193A1 (de) * 2005-09-29 2008-06-25 Wyeth a Corporation of the State of Delaware Benzothiadiazolyphenylalkylamin-derivate für die behandlung von mittels monoamin-wiederaufnahme verbesserten leiden
EP2015765A4 (de) * 2006-03-28 2011-11-23 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von erkrankungen
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes

Also Published As

Publication number Publication date
NZ587896A (en) 2011-09-30
AU2009215541A1 (en) 2009-08-27
WO2009105507A3 (en) 2010-01-14
KR20100137473A (ko) 2010-12-30
NZ594937A (en) 2013-03-28
MX2010009110A (es) 2010-11-30
EP2285818A4 (de) 2011-08-17
EP2285818A2 (de) 2011-02-23
CN102007139A (zh) 2011-04-06
CA2715192A1 (en) 2009-08-27
WO2009105507A2 (en) 2009-08-27
IL207668A0 (en) 2010-12-30
JP2011512414A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
IL243574B (en) A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
BR112013013417A2 (pt) composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal
BRPI0719276A2 (pt) Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
EP2406765A4 (de) Vorrichtung zur verabreichung eines arzneimittels an einen patienten bei eingeschränktem patientenseitigen zugriff auf das arzneimittel im falle von kontraindikationen sowie anwendungsverfahren dafür
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
HK1165294A1 (zh) 用於治療假性延髓情緒及含嗎啡喃類化合物及抗抑鬱劑的組合
BRPI0812504A2 (pt) Composto, composição farmacêutica e método de profilaxia ou tratamento de doença ou condição associados a receptor de canabinoides em sujeito mamífero
EP2262520A4 (de) Verfahren zur prävention und behandlung von akuter nierenschädigung
BRPI0917004A2 (pt) composto, composição farmacêutica, uso de um composto, e, métodos para melhorar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero em necessidade deste
BRPI0916890A2 (pt) composto, composição farmacêutica, métodos para elicitar um efeito agonista, e um efeito antagonista de um receptor de gip, para tratar condições ou doeças, para tratar distúrbios, para tratar ou prevenir causas secundárias de diabete, e para estimular secreção de insulina em um indivíduo, e, uso de um composto
IL213526A0 (en) Methods for treating acute myocardial infarctions and associated disorders
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BRPI0811845A2 (pt) Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
HRP20180531T1 (hr) Antagonisti serotoninskog 5-ht3 receptora za uporabu u liječenju površina vestibularnih lezija
EP2190408A4 (de) Analgetische und entzündungshemmende zusammensetzungen sowie verfahren zur linderung, verhinderung oder behandlung von schmerzen und entzündungen
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
EP2300015A4 (de) Verwendung von gabaa-rezeptor-antagonisten zur behandlung von übermässiger schläfrigkeit und erkrankungen im zusammenhang mit übermässiger schläfrigkeit
SI2355822T1 (sl) Zdravljenje kognitivnih motenj z (R)-7-kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamidom in njegovimi farmacevtsko sprejemljivimi solmi
BRPI0912112A2 (pt) agente para suprimir um efeito indesejável de um analgésico do tipo opióide, agente terapêutico e/ou preventivo para dor, kit, composição farmacêutica, métodos para suprimir um efeito indesejável de um opióide, e para tratar e/ou prevenir a dor, uso de um composto e um opióide, composto, e, combinação
BRPI0908098A2 (pt) Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.